The global industry for Behçet's disease therapeutics is witnessing a period of substantial growth, driven by an increasing prevalence of the disease and advancements in treatment options. The demand for effective therapies to manage the varying symptoms of Behçet's disease is propelling this development. Pharmaceutical companies are actively inv